SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1].
SCD1 inhibitor-3 (compound 17a) (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %[1].
SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index[1].
| Animal Model: | Lewis rats[1] |
| Dosage: | 5 mg/kg |
| Administration: | P.o.; 4 hours |
| Result: | Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %. |
| Animal Model: | Lewis rats[1] |
| Dosage: | 2~10 mg/kg |
| Administration: | P.o.; 4 hours |
| Result: | A dose-responsive reduction of plasma triglycerides desaturation index. |
[1]. Sun S, et al. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors. Bioorg Med Chem. 2015;23(3):455-465.